Literature DB >> 17475624

Silencing of insulin-like growth factor-binding protein-2 in human glioblastoma cells reduces both invasiveness and expression of progression-associated gene CD24.

Tsuyoshi Fukushima1, Tomoaki Tezuka, Takeshi Shimomura, Shinichi Nakano, Hiroaki Kataoka.   

Abstract

Glioblastoma multiforme (GBM) is a malignant brain tumor characterized by rapid growth and extensive invasiveness. Overexpression of insulin-like growth factor-binding protein-2 (IGFBP-2) has been reported in GBM. However, it remains to be determined how IGFBP-2 is involved in the progression of GBM. We utilized short hairpin-RNA (shRNA) expression retroviral vectors to inactivate the IGFBP-2 gene permanently in two human GBM cell lines, U251 and YKG-1. The stable knockdown of IGFBP-2 resulted in decreased invasiveness, decreased saturation density of the cells in vitro, and decreased tumorigenicity in nude mice. Transcriptional profiling of both lines revealed several genes that were significantly down-regulated by inactivation of IGFBP-2. One such gene was CD24, which has been implicated in progression of various cancers. Indeed, CD24 was expressed in most GBM cases and the inactivation of CD24 in GBM cells suppressed cellular invasiveness, as was the case for IGFBP-2. Forced overexpression of CD24 led to increased invasiveness of both IGFBP-2-inactivated GBM cell lines and also A172, a human GBM cell line with low endogenous CD24. Further supporting the inter-relationship between IGFBP-2 and CD24, knockdown of IGFBP-2 suppressed the CD24 promoter activity. Moreover, both CD24 promoter activity and in vitro invasiveness were restored in knockdown cells by transfection with an IGFBP-2 expression plasmid. These results indicate that CD24 is modulated by IGFBP-2 and contributes to IGFBP-2-enhanced invasiveness of GBM cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17475624     DOI: 10.1074/jbc.M609567200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

1.  STAT-Related Profiles Are Associated with Patient Response to Targeted Treatments in Locally Advanced SCCHN.

Authors:  Vassiliki Kotoula; Sofia Lambaki; Despina Televantou; Anna Kalogera-Fountzila; Angelos Nikolaou; Konstantinos Markou; Despina Misailidou; Konstantinos N Syrigos; George Fountzilas
Journal:  Transl Oncol       Date:  2011-02-01       Impact factor: 4.243

2.  CD24 promotes tumor cell invasion by suppressing tissue factor pathway inhibitor-2 (TFPI-2) in a c-Src-dependent fashion.

Authors:  Niko Bretz; Aurelia Noske; Sascha Keller; Natalie Erbe-Hofmann; Thomas Schlange; Alexei V Salnikov; Gerd Moldenhauer; Glen Kristiansen; Peter Altevogt
Journal:  Clin Exp Metastasis       Date:  2011-10-08       Impact factor: 5.150

3.  Aberrant immunostaining pattern of the CD24 glycoprotein in clinical samples and experimental models of pediatric medulloblastomas.

Authors:  Emma Sandén; Cecilia Dyberg; Cecilia Krona; Edward Visse; Helena Carén; Paul A Northcott; Marcel Kool; Nils Ståhl; Annette Persson; Elisabet Englund; John I Johnsen; Peter Siesjö; Anna Darabi
Journal:  J Neurooncol       Date:  2015-03-29       Impact factor: 4.130

4.  Expression of insulin-like growth factor binding protein-2 (IGFBP-2) gene in negative and positive human cytomegalovirus glioblastoma multiforme tissues.

Authors:  Narges Ahani; Mohsen Karimi Arzenani; Reza Shirkoohi; Mohammad Rokouei; Majid Alipour Eskandani; Abbas Nikravesh
Journal:  Med Oncol       Date:  2013-12-19       Impact factor: 3.064

5.  Artemin Reduces Sensitivity to Doxorubicin and Paclitaxel in Endometrial Carcinoma Cells through Specific Regulation of CD24.

Authors:  Vijay Pandey; Yewon Jung; Jian Kang; Michael Steiner; Peng-Xu Qian; Arindam Banerjee; Murray D Mitchell; Zheng-Sheng Wu; Tao Zhu; Dong-Xu Liu; Peter E Lobie
Journal:  Transl Oncol       Date:  2010-08-01       Impact factor: 4.243

6.  High IGFBP2 expression correlates with tumor severity in pediatric rhabdomyosarcoma.

Authors:  Lucia Tombolan; Francesca Orso; Vincenza Guzzardo; Silvia Casara; Angelica Zin; Massimo Bonora; Chiara Romualdi; Carlotta Giorgi; Gianni Bisogno; Rita Alaggio; Paolo Pinton; Cristiano De Pittà; Daniela Taverna; Angelo Rosolen; Gerolamo Lanfranchi
Journal:  Am J Pathol       Date:  2011-09-13       Impact factor: 4.307

7.  Regulation of pericellular proteolysis by hepatocyte growth factor activator inhibitor type 1 (HAI-1) in trophoblast cells.

Authors:  Kazuyo Kohama; Makiko Kawaguchi; Tsuyoshi Fukushima; Chen-Yong Lin; Hiroaki Kataoka
Journal:  Hum Cell       Date:  2012-12-18       Impact factor: 4.174

8.  Molecular profiling reveals similarities and differences between primitive subsets of hematopoietic cells generated in vitro from human embryonic stem cells and in vivo during embryogenesis.

Authors:  Giorgia Salvagiotto; Yun Zhao; Maxim Vodyanik; Victor Ruotti; Ronald Stewart; Marco Marra; James Thomson; Connie Eaves; Igor Slukvin
Journal:  Exp Hematol       Date:  2008-10       Impact factor: 3.084

9.  A novel splice variant of GLI1 that promotes glioblastoma cell migration and invasion.

Authors:  Hui-Wen Lo; Hu Zhu; Xinyu Cao; Amy Aldrich; Francis Ali-Osman
Journal:  Cancer Res       Date:  2009-08-25       Impact factor: 12.701

10.  PAPA-1 Is a nuclear binding partner of IGFBP-2 and modulates its growth-promoting actions.

Authors:  Kenichi Miyako; Laura J Cobb; Malik Francis; Alden Huang; Bonnie Peng; John E Pintar; Hiroyoshi Ariga; Pinchas Cohen
Journal:  Mol Endocrinol       Date:  2008-12-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.